Related Experiment Video
Updated: Mar 16, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
Chih-Hung Hsu1, Ying-Chun Shen2, Yu-Yun Shao1
1Department of Oncology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Abstract:
The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase and the vascular endothelial growth factor receptor, in 2007 for treating advanced hepatocellular carcinoma (HCC) has generated considerable enthusiasm in drug development for this difficult-to-treat disease. However, because several randomized Phase III studies testing new multikinase inhibitors failed, sorafenib remains the standard of first-line systemic therapy for patients with advanced HCC. Field practice studies worldwide have suggested that in daily practice, physicians are adopting either a preemptive dose modification or a ramp-up strategy to improve the compliance of their patients. In addition, accumulating data have suggested that patients with Child-Pugh class B liver function can tolerate sorafenib as well as patients with Child-Pugh class A liver function, although the actual benefit of sorafenib in patients with Child-Pugh class B liver function has yet to be confirmed. Whether sorafenib can be used as an adjunctive therapy to improve the outcomes of intermediate-stage HCC patients treated with transcatheter arterial chemoembolization or early-stage HCC patients after curative therapies is being investigated in several ongoing randomized Phase III studies. An increasing number of studies have reported that sorafenib exerts "off-target" effects, including the modulation of signaling pathways other than Raf/MEK/ERK pathway, nonapoptotic cell death mechanisms, and even immune modulation. Finally, although sorafenib in combination with chemotherapy or other targeted therapies has the potential to improve therapeutic efficacy in treating HCC, it also increases toxicity. Additional clinical studies are warranted to determine useful sorafenib-based combinations for the treatment of advanced HCC.
Insights
Sorafenib is the standard first-line treatment for advanced hepatocellular carcinoma (HCC). Research explores dose modifications, use in varying liver function, adjunctive therapies, off-target effects, and combinations to improve HCC treatment outcomes.
Area of Science:
- Hepatocellular Carcinoma Research
- Oncology Drug Development
- Multikinase Inhibitor Therapy
Background:
- Sorafenib, a multikinase inhibitor, was approved in 2007 for advanced hepatocellular carcinoma (HCC).
- Despite numerous failed trials of other multikinase inhibitors, sorafenib remains the standard first-line therapy for advanced HCC.
- Clinical practice involves dose modification strategies to enhance patient compliance.
Purpose of the Study:
- To review the current status and future directions of sorafenib in advanced HCC treatment.
- To explore sorafenib's efficacy, safety, and novel applications in HCC management.
- To discuss ongoing research into sorafenib's off-target effects and combination therapies.
Main Methods:
- Review of randomized Phase III studies and field practice data.
- Analysis of clinical trial outcomes and patient tolerability data.
- Investigation of sorafenib's molecular mechanisms and potential synergistic effects.
Main Results:
- Sorafenib is the established first-line treatment for advanced HCC.
- Physicians utilize dose modification strategies in clinical practice.
- Patients with Child-Pugh class B liver function show similar tolerability to class A, though benefit requires confirmation.
- Ongoing studies are evaluating sorafenib in earlier stages and as an adjunctive therapy.
- Sorafenib exhibits off-target effects, including immune modulation and non-apoptotic cell death induction.
- Combination therapies with sorafenib show potential for improved efficacy but increased toxicity.
Conclusions:
- Sorafenib remains a cornerstone for advanced HCC, with ongoing research focusing on optimizing its use and exploring novel therapeutic combinations.
- Further clinical studies are essential to confirm benefits in specific patient groups and to establish safe and effective combination regimens.
- Understanding sorafenib's multifaceted mechanisms, including off-target effects, is crucial for advancing HCC treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers